Typical Testing Data/Standard Curve (for reference only)
Human Dystroglycan (DAG1) ELISA Kit | DAG1 elisa kit
Human Dystroglycan (DAG1) ELISA Kit
Typical Testing Data/Standard Curve (for reference only)
Typical Testing Data/Standard Curve (for reference only)
Principle of the Assay: DAG1 ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-DAG1 antibody and an DAG1-HRP conjugate. The assay sample and buffer are incubated together with DAG1-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the DAG1 concentration since DAG1 from samples and DAG1-HRP conjugate compete for the anti-DAG1 antibody binding site. Since the number of sites is limited, as more sites are occupied by DAG1 from the sample, fewer sites are left to bind DAG1-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The DAG1 concentration in each sample is interpolated from this standard curve.
NCBI and Uniprot Product Information
NCBI Description
Dystroglycan is a laminin binding component of the dystrophin-glycoprotein complex which provides a linkage between the subsarcolemmal cytoskeleton and the extracellular matrix. Dystroglycan 1 is a candidate gene for the site of the mutation in autosomal recessive muscular dystrophies. The dramatic reduction of dystroglycan 1 in Duchenne muscular dystrophy leads to a loss of linkage between the sarcolemma and extracellular matrix, rendering muscle fibers more susceptible to necrosis. Dystroglycan also functions as dual receptor for agrin and laminin-2 in the Schwann cell membrane. The muscle and nonmuscle isoforms of dystroglycan differ by carbohydrate moieties but not protein sequence. Alternative splicing results in multiple transcript variants all encoding the same protein.[provided by RefSeq, Apr 2010]
Uniprot Description
DAG1: a cytoskeletal protein that functions as a laminin receptor. Provides a linkage between the subsarcolemmal cytoskeleton and the extracellular matrix. May be involved in autosomal recessive muscular dystrophies. Its dramatic reduction in Duchenne muscular dystrophy leads to a loss of linkage between the sarcolemma and extracellular matrix, rendering muscle fibers more susceptible to necrosis. Dystroglycan also functions as dual receptor for agrin and laminin-2 in the Schwann cell membrane. Binds to several types of arenaviruses. Is a target for the entry of Mycobacterium leprae into peripheral nerve Schwann cells. The muscle and nonmuscle isoforms of dystroglycan differ by carbohydrate moieties but not protein sequence.
Protein type: Membrane protein, integral; Cytoskeletal; Motility/polarity/chemotaxis
Chromosomal Location of Human Ortholog: 3p21
Cellular Component: dystroglycan complex; extracellular space; focal adhesion; costamere; basolateral plasma membrane; integral to membrane; extracellular region; lipid raft; nucleoplasm; dystrophin-associated glycoprotein complex; postsynaptic membrane; cell-cell adherens junction; cytoskeleton; lamellipodium; cytoplasm; plasma membrane; basement membrane; sarcolemma; filopodium
Molecular Function: tubulin binding; viral receptor activity; laminin-1 binding; protein binding; structural constituent of muscle; protein complex binding; SH2 domain binding; calcium ion binding; actin binding; alpha-actinin binding; vinculin binding
Biological Process: response to peptide hormone stimulus; nerve maturation; extracellular matrix organization and biogenesis; entry of virus into host cell; negative regulation of protein kinase B signaling cascade; cytoskeletal anchoring; negative regulation of MAPKKK cascade; virus-host interaction; membrane protein ectodomain proteolysis; morphogenesis of an epithelial sheet; calcium-dependent cell-matrix adhesion; NLS-bearing substrate import into nucleus; negative regulation of cell migration; myelination in the peripheral nervous system
Disease: Muscular Dystrophy-dystroglycanopathy (limb-girdle), Type C, 9; Muscular Dystrophy-dystroglycanopathy (congenital With Brain And Eye Anomalies), Type A, 9
Research Articles on DAG1
Similar Products
Product Notes
The Human DAG1 dag1 (Catalog #AAA7209388) is an ELISA Kit and is intended for research purposes only. The product is available for immediate purchase. The AAA7209388 ELISA Kit recognizes Human DAG1. It is sometimes possible for the material contained within the vial of "Dystroglycan (DAG1), ELISA Kit" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
